Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 25Recurrence 3Smoldering Multiple Myeloma 2Neuroblastoma 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Ganglioneuroblastoma 1

Interventions

Cyclophosphamide 28Temozolomide 25Irinotecan 21dinutuximab 20Topotecan 15Magnetic Resonance Spectroscopy 13Specimen Handling 12Biopsy 12naxitamab 11Granulocyte-Macrophage Colony-Stimulating Factor 113-Iodobenzylguanidine 11Vincristine 10Etoposide 10sargramostim 9Melphalan 9Isotretinoin 9fludarabine 8X-Rays 8Colony-Stimulating Factors 8Carboplatin 8etoposide phosphate 7Phantoms, Imaging 7Doxorubicin 7fludarabine phosphate 6Stem Cell Transplantation 6Nuclear Medicine Department, Hospital 6Eflornithine 6Thiotepa 5Granulocyte Colony-Stimulating Factor 5Filgrastim 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × iberdomide × 1 year × Clear all
NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
76 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡